Imago BioSciences Inc investor relations material
Listen to the latest call from Imago BioSciences Inc
Imago BioSciences, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme used in the production of blood cells in the bone marrow. We are conducting clinical trials for bomedemstat which is being developed as a treatment for myeloproliferative neoplasms (MPNs).
Ticker
IMGOCountry
USAbout
IR-page